首页> 美国卫生研究院文献>Progress in Biomaterials >Formulation physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier
【2h】

Formulation physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier

机译:人胰岛素微球作为潜在口服载体的配制理化特性和体外评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AbstractThe objective of the present investigation was to formulate and characterize the human insulin entrapped Eudragit S100 microspheres containing protease inhibitors and to develop an optimized formulation with desirable features. A w/o/w multiple emulsion solvent evaporation technique was employed to produce microspheres of human insulin using Eudragit S-100 as coating material and polyvinyl alcohol as a stabilizer. The resultant microspheres were evaluated for drug-excipient compatibility, encapsulation efficiency, particle size, surface morphology, micromeritic properties, enteric nature, and in vitro drug release studies. Micromeritic properties indicated good flow properties and compressibility. In present investigation formulation F6 with drug/polymer ratio (1:100) was found to be optimal in terms of evaluated parameters where it showed a significantly higher percentage of encapsulation efficiency (76.84%) with minimal drug release (3.25%) in an acidic environment. The optimized formulation (F6) also possessed good spherical shape and particle size (57.42 µm) required to achieve the desired in vitro drug release profile at pH 7.4. The results confirmed that human insulin-loaded Eudragit S-100 microspheres containing protease inhibitor possessed good encapsulation efficiency, pH dependant controlled release carrying encapsulated insulin to its optimum site of absorption. This ultimately resulted in enhanced insulin absorption and biological response.
机译:摘要本研究的目的是配制和表征包含蛋白酶抑制剂的人胰岛素包埋的Eudragit S100微球,并开发具有所需功能的优化制剂。采用w / o / w多重乳液溶剂蒸发技术,以Eudragit S-100为包衣材料和聚乙烯醇为稳定剂,生产人胰岛素微球。评价所得微球的药物-赋形剂相容性,包封效率,粒径,表面形态,微胶质性质,肠溶性和体外药物释放研究。微粒性能表明良好的流动性和可压缩性。在目前的研究中,发现药物/聚合物比为(1:100)的F6在评估参数方面是最佳的,在酸性条件下,它显示出更高的包封效率百分比(76.84%),而药物释放最少(3.25%)环境。优化的配方(F6)还具有良好的球形和粒径(57.42 µm),以在pH 7.4下达到所需的体外药物释放曲线。结果证实,含有蛋白酶抑制剂的载人胰岛素的Eudragit S-100微球具有良好的包封效率,pH依赖的控释将包封的胰岛素携带到其最佳吸收位点。这最终导致胰岛素吸收和生物学反应增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号